Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sandoz Group AG
Industry Sector: HealthTechnology
CEO: Richard Saynor
Number Of Employees: 23,000
Enterprise Value: $21,571,225,344
PE Ratio: 6072.58
Exchange/Ticker 1: SIX:SDZ
Exchange/Ticker 2: Pink:SDZNY
Latest Market Cap: $18,346,217,930
BioCentury | Mar 15, 2025
Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
BioCentury | Feb 20, 2025
Management Tracks
Bourla becomes chair of PhRMA
Plus: Steve Worland named CEO of Atomwise and updates from Ona, Cidara and Biosion
BioCentury | Feb 4, 2025
Management Tracks
Francisco Ballester to retire from Sandoz
Plus: Boundless Bio hires a new CMO and updates from Avanzanite and George Medicines
BioCentury | May 22, 2024
Market Access
What’s behind CVS’s changing adalimumab strategy
Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira
BioCentury | Mar 7, 2024
Management Tracks
Sandoz names new CFO, board nominations
Plus: McKinsey vet Littlejohns becomes Velsera’s CEO and updates from MBrace, Fibrobiologics, NeoVac and Mithra
BioCentury | Feb 2, 2024
Management Tracks
New CFOs for Sanofi, Takeda
Plus: NextPoint names Eisai vet Cheung CEO, Love joins Gilead board and updates from Acumen, Maxion, EnteroBiotix, Remix
BioCentury | Feb 2, 2024
Market Access
Manufacturers should think twice before developing a self-administered biosimilar
Samsung Bioepis report says Humira has 97% of the adalimumab market almost a year after it lost exclusivity
BioCentury | Jan 23, 2024
Deals
Deals roundup: Coherus sharpens oncology focus, BridgeBio bolsters balance sheet and more
BioCentury’s weekly roundup of biopharma deals, Jan. 16-22
BioCentury | Oct 12, 2023
Product Development
Slimmed down Novartis is now poised to grow value, says CEO Narasimhan
How Vas Narasimhan is managing change as he continues to chart a new course for the pharma
BioCentury | Oct 5, 2023
Regulation
Oct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastoma
Plus: ClavystBio launches space for start-ups in Singapore and updates from Novavax, Iambic, Sandoz, Shorla and more
Items per page:
1 - 10 of 10